The SENSCIS Trial (NCT02597933) was a phase 3 randomised, double-blind, placebo controlled study, which investigated the efficacy and safety of nintedanib in the treatment of patients with systemic sclerosis associated interstitial lung disease. In this touchIMMUNOLOGY interview, it was a pleasure to talk with Dr. Janet Pope (University of Western Ontario, London, ON, Canada) to discuss her analysis, which assessed outcomes by organ damage using a modified version of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) and Organ Damage: Data from the SENSCIS Trial.‘ (Abstract number: 1528) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What is the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) and what are its aims? (0:16)
- Could you give us a brief overview of the SENSCIS study and its primary findings? (0:49)
- What were the aims and design of this analysis? (2:32)
- How effective were the SCTC-DI scores as a measure of organ damage? (3:58)
- What did the findings teach us about the efficacy of nintedanib? (5:36)
Disclosures: Janet Pope has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
